Paper Details

  1. Home
  2. Paper Details

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.

Author: HäringDieter A, KieseierBernd C, KiraJun-Ichi, KurosawaTakayoshi, MerschhemkeMartin, NakaharaJin, PingiliRatnakar, RamanathanKrishnan, SaidaTakahiko, SazonovDenis V, SuWendy, TsumiyamaIsao, WilliRoman, ZalesakMartin

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ofatumumab demonstrated superior efficacy compared to placebo in reducing the number of gadolinium-enhancing (Gd+) T1 lesions in patients with relapsing multiple sclerosis (RMS). The benefits of ofatumumab were sustained through 48 weeks, and switching to ofatumumab after 24 weeks led to rapid clinical and radiological improvements.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home. OBJECTIVE: To investigate the efficacy and safety of ofatumumab in RMS patients from Japan and Russia. METHO...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/13524585211055934

データ提供：米国国立医学図書館（NLM）

Ofatumumab: A Promising Treatment for Relapsing Multiple Sclerosis

The study evaluates the efficacy and safety of ofatumumab, a fully human anti-CD20 monoclonal antibody, in patients with relapsing multiple sclerosis (RMS) from Japan and Russia. This phase 2 clinical trial compared the effects of ofatumumab to placebo over a 24-week period, followed by an open-label extension phase. The study found that ofatumumab demonstrated superior efficacy compared to placebo in reducing the number of gadolinium-enhancing (Gd+) T1 lesions, a key marker of MS disease activity. The study also highlighted the sustained effectiveness of ofatumumab over 48 weeks and the rapid clinical and radiological benefits observed in patients switching to ofatumumab after 24 weeks. The safety profile of ofatumumab was consistent with previous pivotal trials.

Ofatumumab: A New Hope for Relapsing Multiple Sclerosis Patients

The results of this study offer encouraging news for patients with RMS, demonstrating the potential of ofatumumab as a safe and effective treatment option. The study's findings suggest that ofatumumab can significantly reduce disease activity and improve clinical outcomes in patients with RMS, offering a potential avenue for better disease management. The study also highlights the importance of continued research to refine treatment strategies and optimize patient outcomes for individuals with MS.

Living with Multiple Sclerosis: A Journey of Hope and Resilience

This study highlights the importance of ongoing research and development in the field of neurology, as it continues to unveil new and innovative therapies for complex conditions like MS. While there is no cure for MS, research continues to explore new avenues for treatment and management, offering hope for a better future for patients. The study's findings also underscore the importance of patient-centered care, ensuring that individuals with MS receive personalized treatment plans that meet their unique needs and goals.

Dr.Camel's Conclusion

This study sheds light on the promising potential of ofatumumab for the treatment of RMS. It's a journey of discovery, much like a camel traversing the vast desert, seeking out new resources and solutions. The findings offer hope for a future where RMS can be effectively managed, allowing patients to lead fulfilling and independent lives.

Date :
  1. Date Completed 2022-06-13
  2. Date Revised 2022-06-15
Further Info :

Pubmed ID

34787005

DOI: Digital Object Identifier

10.1177/13524585211055934

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.